The following criteria should be met for a desensitization protocol to be considered eligible for coverage:

Renal Transplant

1.  A suitable non-reactive live or cadaveric donor is unavailable.

A.  Living Donors - patients should exhibit:

• A current positive cross-match or may be defined by any of the following:
  • Flow cytometric crossmatch (FCXM) positive for T and/or B cells
  • National Institute of Health Complement dependent cytotoxicity (NIH-CDC) positive and dithiothreitol (DTT) treated
  • Antihuman globulin (AHG-CDC) assay positive
• ABO blood group incompatibility (ABOi) with or without splenectomy. May be defined as isoagglutinin titer >1:4

B.  Deceased Donors

• Panel reactive antibody (PRA) of HLA >50% or
• Donor specific antibody (DSA) positive or
• ABO blood group incompatibility (ABOi) with or without splenectomy

Various protocols (e.g., Johns Hopkins University Hospital, Cedars-Sinai Medical Center, etc.) utilize the following medications/procedures in desensitization treatment:

IVIG

• prior to solid organ transplant, treatment of patients at high risk of antibody-mediated rejection, including highly sensitized patients, and those receiving an ABO incompatible organ
• following solid-organ transplant, treatment of antibody-mediated rejection

Plasmapheresis

• prior to solid organ transplant, treatment of patients at high risk of antibody-mediated rejection, including highly sensitized patients, and those receiving an ABO incompatible organ
• following solid-organ transplant, treatment of antibody-mediated rejection

Rituximab (Rituxan®)

• prior to solid organ transplant, treatment of patients at high risk of antibody-mediated rejection, including highly sensitized patients, and those receiving an ABO incompatible organ
• the efficacy of more than two infusions in 48 weeks is unknown

The use of a desensitization treatment protocol that does not meet these criteria or for any other transplant other than renal is considered experimental/investigational, and therefore, non-covered. A participating, preferred, or network provider can bill the member for the non-covered service.

NOTE:

Coverage is determined according to individual or group customer benefits.

See Medical Policy Bulletin I-14 on Intravenous Immune Globulin.

See Medical Policy Bulletin S-11 on Pheresis Therapy.

Description

Sensitization is a growing problem in kidney transplantation. Approximately 30% of patients on the deceased donor waiting list have high levels of preformed anti-HLA antibodies. Alloantibodies develop after exposure to foreign antigens in the setting of blood transfusion, pregnancy and previous organ transplantation. With a growing number of patients returning to dialysis after a failed allograft, a different pattern has emerged over the past 10 years with previous transplantation now the leading cause of sensitization.  These numbers are projected to grow with the increasing disparity between organ supply and demand, the utilization of extended criteria donors and the high rate of graft loss from chronic allograft injury.

Presensitization poses a difficult problem in kidney transplantation. Highly sensitized patients face extended waiting times on dialysis thus, depriving them of improved quality of life and survival afforded by early kidney transplantation. After transplantation, they often have inferior outcomes compared with unsensitized patients due to a higher risk of rejection and the need for intensified immunosuppression. As such, the challenge of finding suitable organs for highly sensitized patients has renewed interest in developing novel strategies to detect and eliminate reactive alloantibodies to allow for a successful transplantation.

The two main strategies utilized over the years in overcoming sensitization are physical removal of alloantibodies using plasmapheresis and immunomodulation using intravenous immune-globulin (IVIG). In the early eighties, after it was shown that renal transplantation may be successful in patients with a negative crossmatch despite having historically positive reactivity; several strategies were developed to remove anti-HLA antibodies. Plasmapheresis (PP) or immunoadsorption (IA) were used to eliminate preformed antibodies in highly sensitized patients using protocols based on those used for Goodpasture’s syndrome to remove and prevent resynthesis of antiglomerular basement membrane antibodies.

Although these methods successfully removed anti-HLA antibodies, initial results were limited by resynthesis of antibodies and high rates of rejection and graft loss. It was clear that the effects of these treatments were temporary and unpredictable, especially in patients with high alloantibody titers and, current immunosuppressive drugs that are mainly centered on T cell mechanisms are inadequate in suppressing resynthesis of alloantibodies.

Recent application of solid-phase antibody screening techniques now allows for more sensitive screening of donor specific antibodies that may not be readily detected by conventional cytotoxic assays. Protocols for desensitization have also been developed in several centers. Although there are variations in strategies, the use of IVIG has been the primary immune-modulating agent integrated with other adjunctive therapies including plasmapheresis.

While current desensitization protocols have made possible successful transplantation in highly sensitized patients, there are limitations. Acute rejection rates remain high within the first 12 months and, it is also evident that response to treatment is not consistent on all patients. The reasons for these are not clear but maybe confounded by factors such as cause of sensitization, DSA class, techniques used to detect anti HLA antibodies, and continued immunologic stimulus from a failed allograft. In many cases, low levels of donor specific antibodies persist despite treatment and, it is often difficult to determine acceptable donor specific antibody levels that will allow successful engraftment. On the other hand, hyperacute rejection is rare and early rejections are often salvaged with additional IVIG/PP treatments.

NOTE:

This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.

Under the Federal Employee Program, all services that utilize FDA-approved drugs, devices, or biological products are eligible when intended for the treatment of a serious life-threatening condition and when medically necessary and appropriate for the patient's condition.

Lockwood CM, Rees AJ, Pearson TA, et al. Immunosuppression and plasma exchange in the treatment of Goodpasture’s syndrome. Lancet. 1976;1:711.

Cardella CJ, Falk JA, Nicholson MJ, et al. Lancet. 1982;2:1240.

Gjorstrup P. Anti HLA antibody removal in hyperimmunized ESRF patients to allow transplantation. The collaborative study group on Anti-HLA antibody removal. Transp Proc. 1991;23:392.

Marchalonis JJ, Kaymaz H, Dedeoglu F, et al. Human autoantibodies reactive with synthetic autoantibodies from T cell receptor beta chain. Proc Natl Acad Sci. USA. 1992;89:3325.

Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA specific alloantibodies by high-dose intravenous immunoglobulin (IVIg): a potential tool for transplantation of immunized patients. Transplantation. 1993;56:335.

Blasczyk R, Westhoff U, Gross-Wilde H. Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations. Lancet. 1993;341:789.

Hurez V, Kaveri SV, Mouhoub A, et al. Anti-CD4 activity of normal human immunoglobulin F for therapeutic use (Intravenous immunoglobulin, IVIg). Ther Immunol. 1994;139:21.

Abe Y, Horiuchi A, Miyake M, et al. Anti-cytokine nature of human immunoglobulin: one possible mechanism of the clinical effect of intravenous therapy. Immunol Rev. 1994;139:5.

Miletic VD, Hester CG, Frank MM. Regulation of complement activity by immunoglobulin. J Immunol. 1996;156:748.

Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int. 2000;58:1311.

Vanderlugt CL, Rahbe SM, Elliott PJ, et al. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteosome inhibitor PS-519. J Autoimmun. 2000;14:205.

Hardy S, Lee S, Terasaki PI. Sensitization. Clinical Transpl. 2001;271.

Luo H, Wu Y, Qi S, et al. A proteosome inhibitor effectively prevents mouse heart allograft rejection. Transplantation. 2001;72:196.

Casadei DH, del C Rial M, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation. 2001;71(1):53-8.

Samaniego M, Zachary AA, Lucas D, et al. Early allograft outcomes in patients with antibody mediated rejection treated with rituximab: a single center experience. Am J Transplant. 2002;2(3):259.

Sarwal M, Chua MS, Kambhan N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med. 2003;349:125.

Jordan SC, Vo AA, Nast CC, et al. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Clin Transpl. 2003;193-8.

Becker YT, Becker BN, Pirsch JD, et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant. 2004;4:996.

Montgomery RA, Simpkins CE, Zachary AA, et al. Anti-CD20 rescue therapy for kidneys undergoing antibody-mediated rejection. Am J Transplant. 2004;4(8):258.

Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. safety, pharmacodynamics, and pharmacokinetics. Transplantation. 2004;77:542-8.

Jordan SC, Tyan D, Stablein D, et al.  Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004;15:3256-62.

Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center’s perspective. Pediatr Transplant. 2004;8(6):535-42.

Jordan SC, Vo AA, Tyan D, et al. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant. 2005;9(3):408-15.

Lehrich RW, Rocha PN, Reinsmoen N, et al. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: Experience in renal allograft transplantation. Hum Immunol. 2005;66(4):350-8.

Dean P, Gloor J, Stegall M. Conquering absolute contraindications to transplantation: Positive crossmatch and ABO–incompatible kidney transplantation. Surgery. 2005;137:269.

Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N Eng J Med. 2005;352:2487.

Chauhan D, Catley L, Li G, et al. A novel orally active proteosome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005;8:407.

Shapiro R, Basu A, Tzan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or Alemtuzumab. J Am Coll Surg. 2005;200:505-515.

Ibernon M, Gil-Vernet S, Carrera M, et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant Proc. 2005;37(9):3743-5.

Cenci S, Mezghrani A, Cascio P. Progressively impaired proteosomal capacity during terminal plasma cell differentiation. EMBO J. 2006;25:1104.

Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant. 2006;6:569.

Vaidya S, Partlow D, Susskind B, et al. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay. Transplantation. 2006;82:1524.

Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;8:3053.

Pescovitz MD. Rituximab, an Anti-CD20 monoclonal antibody: History and mechanisms of action. Am J of Transplant. 2006;6:859.

Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006;6:346-51.

Beimler JH, Susal C, Zeier M. Desensitization strategies enabling successful renal transplantation in highly sensitized patients. Clin Transplant. 2006;20(17):7-12.

Nishio M, Fujimoto K, Yamamoto S, et al. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjunct to autologous stem cell transplantation. Br J Haematol. 2007;137:349.

2007 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network of Organ Sharing, Richmond, VA: University Renal Research and Education Association, Ann Arbor.

Matignon M, Tagnaouti M, Audard V, et al. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients. Transplant Proc. 2007;39:2565-7.

Nencioni A, Grunebach F, Patrone F, et al. Proteosome inhibitors: antitumor effects and beyond. Leukemia. 2007;21:30.

Van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation. 2008;85:1086.

Gupta A, Iveson V, Varagunam M, et al. Pretransplantation donor-specific antibodies in cytotoxic negative crossmatch kidney transplant: are they relevant? Transplantation. 2008;85:1200.

Everly M, Everly J, Susskind B, et al. Bortezomib provides effective therapy for antibody and cell mediated acute rejection. Transplantation. 2008;86:1754.

Vo AA, Luvosky M, Toyoda M, et al.  Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359:242-51.

Lee R, Peng A, Villicana R, et al. Rates of acute rejection (AR) and treatment outcomes in highly-HLA sensitized patients (HS) transplanted after desensitization with IVIG + rituximab. Am J Transplant. 2008;8:238. Abstract.

Amante AJ, Ejercito R. Management of highly sensitized patients: Capitol Medical Center experience.  Transplant Proceed. 2008;40:2274-80.

Jordan S, Peng A, Vo A. Therapeutic strategies in management of the highly HLA-Sensitized and ABO-incompatible transplant recipients. Contrib Nephrol. 2009;162:13.

Gloor JM, DeGoey SR, Pineda AA, et al.  Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant. 2003;3:1017-23.

Yoon HE, Hyoung BJ, Hwang HS, et al.  Successful renal transplantation with desensitization in highly sensitized patients: a single center experience. J Korean Med Sci. 2009;24(1):S148-55.

Kim SM, Lee C, Lee JP, et al. Kidney transplantation in sensitized recipients: a single center experience.  J Korean Med Sci. 2009;24(1):S143-7.

Vo AA, Cao K, Lai C, et al. Long term outcomes of highly-HLA sensitized patients receiving desensitization with IVIG and single-dose rituximab. Abstract presented at American Transplant Congress, Boston, MA; 2009 June 1.

Vo AA, Cao K, Lai C, et al. Characteristics of patients who developed antibody mediated rejection post-transplant after desensitization with IVIG + rituximab: analysis of risk factors & outcomes. Abstract presented at American Transplant Congress, Boston, MA; 2009 June 2.

Vo AA, Toyoda M, Ge S, et al. Long term outcomes of deceased donor transplants in highly-HLA sensitized patients desensitized with IVIG + single-dose rituximab. Abstract presented at American Transplant Congress, Boston, MA; 2009 June 1.

Peng A, Villicana R, Vo A, et al. Long term (1, 3, 5, 7, and 9 year) outcomes of desensitization of highly-HLA sensitized patients awaiting deceased donor transplantation. Abstract presented at American Transplant Congress, Boston, MA; 2009 June 2.